Astrazeneca Pharma India Ltd Quarterly Results: Standalone & Consolidated Reports

Quarterly Results

Results Snapshot

YoYQoQ

Figures in Cr

Standalone Quarterly Results

Mar'26

Dec'25

Sep'25

Jun'25

Mar'25

Dec'24

Sep'24

Quarterly Analysis Highlights - QoQ

Net Sales

QoQ Growth in quarter ended Mar 2026 is -5.39% vs 9.39% in Dec 2025

Standalone Net Profit

QoQ Growth in quarter ended Mar 2026 is 37.71% vs -39.89% in Dec 2025

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Mar 2026 is 35.87% vs -40.37% in Dec 2025

Interest

QoQ Growth in quarter ended Mar 2026 is 92.45% vs 58.21% in Dec 2025

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Mar 2026 has improved from Dec 2025

Compare Quarterly Results Of Astrazeneca Phar With

Select Peers

Figures in Cr

Standalone Quarterly Results

Change(INR)

Change(%)

Net Sales

578.61

776.25

-197.64

-25.46%

Other Operating Income

0.00

Total Operating income

578.61

776.25

-197.64

-25.46%

Raw Material Cost

0.00

230.79

-230.79

-100.00%

Purchase of Finished goods

312.31

0.00

312.31

(Increase) / Decrease In Stocks

81.94

38.50

43.44

112.83%

Employee Cost

45.70

95.27

-49.57

-52.03%

Power Cost

0.00

Manufacturing Expenses

0.00

51.72

-51.72

-100.00%

Selling and Distribution Expenses

30.13

0.00

30.13

Other Expenses

47.62

53.06

-5.44

-10.25%

Total Expenditure (Excl Depreciation)

517.70

469.34

48.36

10.30%

Operating Profit (PBDIT) excl Other Income

60.91

306.91

-246.00

-80.15%

Other Income

5.95

12.46

-6.51

-52.25%

Operating Profit (PBDIT)

66.86

319.37

-252.51

-79.07%

Interest

2.04

7.23

-5.19

-71.78%

Exceptional Items

-1.08

0.00

-1.08

Gross Profit (PBDT)

63.74

312.14

-248.40

-79.58%

Depreciation

5.60

25.09

-19.49

-77.68%

Profit Before Tax

58.14

287.04

-228.90

-79.74%

Tax

13.26

74.52

-61.26

-82.21%

Provisions and contingencies

0.00

Profit After Tax

44.88

212.52

-167.64

-78.88%

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

44.88

212.52

-167.64

-78.88%

Equity Capital

5.00

12.90

-7.90

-61.24%

Face Value

2.00

10.00

0.00

Reserves

0.00

Earnings per share (EPS)

17.95

164.74

-146.79

-89.10%

Diluted Earnings per share

17.95

165.65

-147.70

-89.16%

Operating Profit Margin (Excl OI)

10.53%

39.54%

0.00

-29.01%

Gross Profit Margin

11.02%

40.21%

0.00

-29.19%

PAT Margin

7.76%

27.38%

0.00

-19.62%

Public Share Holdings (%)

0.00%

0.00

0.00%

Pledged Promotor Holding (%)

0.00%

0.00

0.00%

Quarterly - Net Sales

Net Sales 578.61 Cr

in Mar 2026

Figures in Cr

QoQ Growth in quarter ended Mar 2026 is -5.39% vs 9.39% in Dec 2025

YoY Growth in quarter ended Mar 2026 is 20.42% vs 25.39% in Mar 2025

Quarterly - Standalone Net Profit

Standalone Net Profit 44.88 Cr

in Mar 2026

Figures in Cr

QoQ Growth in quarter ended Mar 2026 is 37.71% vs -39.89% in Dec 2025

YoY Growth in quarter ended Mar 2026 is -22.95% vs 47.54% in Mar 2025

Quarterly - Operating Profit (PBDIT)

Operating Profit (PBDIT) 60.91 Cr

in Mar 2026

Figures in Cr

QoQ Growth in quarter ended Mar 2026 is 35.87% vs -40.37% in Dec 2025

YoY Growth in quarter ended Mar 2026 is -29.48% vs 74.87% in Mar 2025

Quarterly - Interest

Interest 2.04 Cr

in Mar 2026

Figures in Cr

QoQ Growth in quarter ended Mar 2026 is 92.45% vs 58.21% in Dec 2025

YoY Growth in quarter ended Mar 2026 is 200.00% vs 1,071.43% in Mar 2025

Quarterly - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) 10.53%

in Mar 2026

Figures in %

QoQ Growth in quarter ended Mar 2026 has improved from Dec 2025

YoY Growth in quarter ended Mar 2026 has fallen from Mar 2025